AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04843774
Drug: SARS-COV-2 mRNA Vaccine
RxNorm normalized name: SARS-CoV-2 mRNA vaccine
DrugBank: SARS-CoV-2 mRNA vaccine (DB15855)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pfizer-BioNTech and Moderna messenger RNA (mRNA)-platform vaccines developed against SARS-CoV-2 virus will be given as standard of care (SOC)
Trial: NCT05687981
Drug: Bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: the use of higher concentration of bupivacaine in ilioinguinal and iliohypogastric nerve block (IINB) might increase the efficacy of postoperative analgesia
Trial: NCT05687981
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 mg dexamethasone
Trial: NCT03712826
Drug: Ustekinumab
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Crohn disease with ustekinumab treatment
Trial: NCT00005010
Drug: Irbesartan
RxNorm normalized name: Irbesartan
DrugBank: Irbesartan (DB01029)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05505708
Drug: hydroxyethyl starch in sodium chloride injection Brand Name: Voluven
DrugBank: Hydroxyethyl Starch (DB09106)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: (6% hydroxyethyl starch 130/0.4 in 0.9% sodium chloride injection) is a clear to slightly opalescent, colorless to slightly yellow, sterile, non-pyrogenic, isotonic solution for intravenous administration using sterile equipment.~Each 100 mL of the solution contains: 6 g of Hydroxyethyl Starch 130/0.4 and 900 mg of Sodium Chloride USP in Water for Injection USP.~In addition, sodium hydroxide, USP, or Hydrochloric acid, USP, has been added to adjust the final pH so the final solution pH is 4.0 to 5.5.
Trial: NCT05505708
Drug: saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Within each 100 mL of 0.9% sodium chloride Injection USP, there is 15.4 mEq of sodium ions and 15.4 mEq of chloride ions. Additionally, the osmolarity is 308 mOsmol/liter, and it has a pH range of 4.5 to 7
Trial: NCT04944771
Drug: Capivasertib
RxNorm normalized name: Capivasertib
DrugBank: Capivasertib (DB12218)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive single oral dose of capivasertib on Day 1 for Treatments A, B, C, D, E and F.
Trial: NCT04944771
Drug: Rabeprazole
RxNorm normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive twice daily oral doses of rabeprazole for 3 days (Days -3 to -1) and a single dose on the morning of Day 1 for Treatment C.
Trial: NCT04726345
Drug: Fexofenadine Hcl 180Mg Tab
RxNorm normalized name: FEXOFENADINE HCL 180MG TAB
DrugBank: Fexofenadine (DB00950)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fexofenadine 180mg tablet to be taken orally once a day until stent removal.
Trial: NCT00002286
Drug: Zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06471959
Drug: Psilocybin
RxNorm normalized name: Psilocybin
DrugBank: Psilocybin (DB11664)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psilocybin in the study comes in the form of the study drug, PYEX. PYEX is a drug substance which is a partially purified fraction of the extract of Psilocybe cubensis mushroom fruiting bodies. It is a mixture of indole alkaloids, other mushroom fruiting body components and stabilization excipients. The major indole alkaloids present include psilocybin and psilocin (dephosphorylated psilocybin). PEX010 is a capsule for oral administration and is manufactured with PYEX (12.5-14.0% psilocybin), excipients, and HPMC (hydroxypropyl methyl cellulose) capsules.
Trial: NCT05816746
Drug: Low-Dose Decitabine plus anti-PD-1
RxNorm normalized name: ethinyl estradiol
DrugBank: Decitabine (DB01262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Decitabine 10mg/d，VD d1-5; PD-1 200mg，d8
Trial: NCT04847440
Drug: ATI-2173
RxNorm normalized name: ATI-355
DrugBank: ATI-355 (DB17923)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth. Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.
Trial: NCT04847440
Drug: Viread
RxNorm normalized name: Viread
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.
Trial: NCT06350448
Drug: Washed Microbiota Transplantation
RxNorm normalized name: Washed Microbiota Transplantation
DrugBank: Washed Microbiota Transplantation (DB15745)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Washed microbiota suspension (5U) delivered through nasogastric tube, nasojejunal tube or oral. Dose and frequency: 5U, three times.
Trial: NCT04793399
Drug: Bosutinib 400 MG Monotherapy
RxNorm normalized name: bosutinib 400 MG
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One cycle (28 days) only with bosutinib 400 mg/day therapy at the beginning of the trial + 12 cycles with bosutinib 400 mg/day therapy after combined therapy
Trial: NCT04793399
Drug: Bosutinib 400 MG + Atezolizumab 840 MG in 14 ML Injection
RxNorm normalized name: atezolizumab
DrugBank: Bosutinib (DB06616)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 12 cycles with bosutinib 400 mg/day plus atezolizumab 1680 mg q4w therapy between the monotherapy bosutinib cycles
Trial: NCT04828135
Drug: Hyperpolarized 129Xenon gas
RxNorm normalized name: xenon-129, hyperpolarized
DrugBank: Xenon (DB13453)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Each xenon dose will be limited to a volume less than 25% of subject lung capacity (TLC),
Trial: NCT05986266
Drug: Carbetocin
RxNorm normalized name: Carbetocin
DrugBank: Carbetocin (DB01282)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To compare efficacy of intravenous carbetocin to intramyometrial injection of adrenaline in decreasing intraoperative blood loss and need for blood transfusion during abdominal myomectomy.
Trial: NCT01288625
Drug: Amifostine
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 500 mg sc, qod, 3 times per week
Trial: NCT05459441
Drug: pemetrexed
RxNorm normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: For patients with brain metastasis from solid tumor that met the inclusion conditions, the Ommaya capsule was placed 2 days later, and the maximum tolerated dose of pemetrexed intrathecal chemotherapy was injected intravaginally at 10mg according to the general situation of the patients and the results of the previous study.
Trial: NCT04718350
Drug: levosimendan at a dose of 6 mcg/kg
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levosimendan will be administered intravenously at a dose of 6 mcg/kg after anesthesia induction
Trial: NCT04718350
Drug: milrinone at a dose of 50 mcg/kg
DrugBank: Milrinone (DB00235)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: milrinone will be administered via inhalation at a dose of 50 mcg/kg after anesthesia induction
Trial: NCT05548985
Drug: Midodrine Oral Tablet
RxNorm normalized name: midodrine Oral Tablet
DrugBank: Midodrine (DB00211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral midodrine tablet (5 mg) 90 min before performing spinal block
Trial: NCT05548985
Drug: Metoclopramide
RxNorm normalized name: Metoclopramide
DrugBank: Metoclopramide (DB01233)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: oral placebo (metoclopramide 10 mg tablet). 90 min before performing spinal block
Trial: NCT05325762
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At 21:00 on the night of tracheal extubation, propofol was administered intravenously with a microinjection pump for 2min. MOAAS/S was used to evaluate subjects 30 seconds after the end of administration.
Trial: NCT05325762
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexmedetomidine was at 21 PM on the day of tracheal extubation: Dexmedetomidine was injected intravenously beginning at 00. During administration, patients were evaluated with MOAA/S every 2min.
Trial: NCT05325762
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: At 21:00 PM on the day of tracheal extubation, normal saline was injected intravenously. During the administration, patients were evaluated with MOAA/S every 2 minutes.
Trial: NCT05267535
Drug: Piromelatine 20 mg
RxNorm normalized name: Piromelatine
DrugBank: Piromelatine (DB12288)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT02412566
Drug: SMOFlipid
RxNorm normalized name: Smoflipid
DrugBank: Soybean oil (DB09422)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy with SMOFlipid will be provided at a targeted dose of 3 gm/kg/day (by continuous infusion). SMOFlipid will be initiated and advanced according to the following guidelines: Day 1 - provide 1 g/kg; Day 2 - provide 2 g/kg; Day 3 - provide 3 g/kg. SMOFlipid will be infused intravenously through either a central or peripheral catheter in conjunction with parenteral nutrition.
Trial: NCT04777162
Drug: Tislelizumab
RxNorm normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: For included participants, tislelizumab would be administrated 200mg q3w iv.
Trial: NCT04777162
Drug: Anlotinib
RxNorm normalized name: Anlotinib
DrugBank: Anlotinib (DB11885)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be administrated with Anlotinib 12mg p.o. d1-d14 q3w.
Trial: NCT03646058
Drug: Buprenorphine
RxNorm normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Buprenorphine, 0.4mg pills, sublingual
Trial: NCT04289558
Drug: Sodium Nitrite
RxNorm normalized name: Sodium Nitrite
DrugBank: Nitrous acid (DB09112)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single 60 minute infusion at 1 of 4 sequential dose levels (0.16, 0.32, 0.64 and 1.28 mcg/kg/minute). The dose amount will depend on when the participant enters the study
Trial: NCT04799002
Drug: Topotecan
RxNorm normalized name: Topotecan
DrugBank: Topotecan (DB01030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topotecan intraocular injection for chemotherapy in retinoblastoma
Trial: NCT04799002
Drug: Melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Melphalan intraocular injection for chemotherapy in retinoblastoma
Trial: NCT05346328
Drug: Injection of A166
RxNorm normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
DrugBank: A166 (DB17413)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.8 mg/kg for each 21 (±3) -day cycle
Trial: NCT05071612
Drug: AD109
RxNorm normalized name: Adefovir dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral administration at bedtime
Trial: NCT05071612
Drug: AD504
RxNorm normalized name: Adefovir dipivoxil
DrugBank: Adefovir dipivoxil (DB00718)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Oral administration at bedtime
Trial: NCT05071612
Drug: Atomoxetine Hydrochloride
RxNorm normalized name: Atomoxetine Hydrochloride
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration at bedtime
Trial: NCT05155124
Drug: Cetuximab + trifluridin tipiracil
RxNorm normalized name: tipiracil / trifluridine
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cetuximab will be administered at a fixed dose of 500 mg/m2 once every 2 weeks; trifluridin tipiracil will be administered in a dose de-escalation design: dose level 1: 35 mg/m2 twice daily on days 1-5 once every 2 weeks; Or dose level 0: 30 mg/m2, twice daily, Days 1-5, once every 2 weeks;
Trial: NCT06131905
Drug: Magnesium Sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium sulfate (DB00653)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 40 mg/kg magnesium sulfate diluted with normal saline to a total volume of 100 ml was administered for 15 min.plus ,An initial bolus dose of 1 mg/kg propofol was administered over 30 is followed by a continuous intravenous infusion of propofol at a maintenance dose of 2 mg/kg/h
Trial: NCT06131905
Drug: Propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: An initial bolus dose of 1 mg/kg propofol was administered over 30 is followed by a continuous intravenous infusion of propofol at a maintenance dose of 2 mg/kg/h
Trial: NCT06133881
Drug: prilocaine
RxNorm normalized name: Prilocaine
DrugBank: Prilocaine (DB00750)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intrathecal 50 mg (2.5 ml) of prilocaine 2% (Takipril, prilocaine hydrochloride 20 mg/mL, hyperbar, Sintetica) + 25 ug fentanyl (0.5 ml).
Trial: NCT06133881
Drug: bupivacaine
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intrathecal 10 mg (2 ml) of bupivacaine 5% (sunnypivacaine hyperbaric bupivacaine 20 mg/4ml + 25 ug fentanyl (0.5 ml
Trial: NCT04739111
Drug: Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) Combined with Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1)
RxNorm normalized name: Anti-VEGF Humanized Monoclonal Antibody
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In the dose-escalation phase, CDP1 400 mg/ m2 will be given in the first week, then 250 mg/m2 will be given evert week. LDP will be given every two weeks with dose climbing of 5 mg/kg, 10 mg/kg, 20 mg/kg. Dose in the dose-expansion phase according to the assesment in the dose-escalation phase.
Trial: NCT04963283
Drug: Cabozantinib
RxNorm normalized name: Cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Cabozantinib is a multi-targeted inhibitor of RTKs. The targets of cabozantinib include several RTKs known to play important roles in tumor cell proliferation and/or tumor neovascularization, namely MET, VEGFR2 (also known as KDR), AXL, and RET. Other recognized targets of cabozantinib include ROS1, TRKA, TRKB, TIE2, TYRO3, and MER, two additional members of the VEGFR family (VEGFR1, VEGFR3), and the closely related RTKs KIT and FLT-3. The mode of action for cabozantinib is similar to other drugs targeting RTKs: binding in a fully reversible manner to a region of the kinase domain (including the ATP-binding site) which forces the kinase activation loop into a pseudo-inactive conformation, thereby inhibiting subsequent catalytic activity.
Trial: NCT04963283
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Nivolumab is a human monoclonal antibody that targets the programmed death-1 (PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor. Nivolumab binds specifically to the human PD-1 receptor and inhibits the interaction of PD-1 with its ligands, programmed death ligands-1 (PD-L1) and 2 (PD-L2), which promotes immune responses and antigen-specific T-cell responses to foreign- and self- antigens. Nivolumab is expressed in Chinese hamster ovary (CHO) cells and is produced using standard mammalian cell cultivation and chromatographic purification technologies.
Trial: NCT04074512
Drug: Copper Histidinate
RxNorm normalized name: Histidine
DrugBank: Copper (DB09130)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Restoring Copper Histidinate levels normally found in the blood to assist in the maintenance of copper homeostasis.
Trial: NCT00334503
Drug: Miglitol
RxNorm normalized name: Miglitol
DrugBank: Miglitol (DB00491)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT05042401
Drug: SHR-1703
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1703 low dose
Trial: NCT05042401
Drug: SHR-1703
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SHR-1703 high dose
Trial: NCT05411107
Drug: Iloprost
RxNorm normalized name: Iloprost
DrugBank: Iloprost (DB01088)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT05173012
Drug: SAGE-324
RxNorm normalized name: SAGE
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAGE-324 oral tablets.
Trial: NCT05173012
Drug: SAGE-324 Matched Placebo
RxNorm normalized name: SAGE
DrugBank: Sage (DB10982)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAGE-324 matched placebo oral tablets.
Trial: NCT04873440
Drug: Manganese Chloride
RxNorm normalized name: Manganese Chloride
DrugBank: Manganese citrate (DB14495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered by inhalation at 0.4mg/kg/d twice a week
Trial: NCT03110484
Drug: Pemetrexed 500 MG
RxNorm normalized name: pemetrexed 500 MG
DrugBank: Pemetrexed (DB00642)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pemetrexed 500 mg/m2
Trial: NCT03110484
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erlotinib 100mg once daily
Trial: NCT06411093
Drug: Conventional treatment including silver nitrate cauterization
RxNorm normalized name: Silver Nitrate
DrugBank: Silver nitrate (DB11080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional treatment including silver nitrate cauterization, with or without topical antiseptics, topical steroids, topical beta-blockers, short-term systemic antibiotics, systemic steroids for 3 months
Trial: NCT06281977
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dose range: 0.3 mcg/kg/hr to 1 mcg/kg/hr.
Trial: NCT06186583
Drug: Pimicotinib（ABSK021）
DrugBank: Icotinib (DB11737)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A standard meal should be given to the subjects in the evening before dosing. Then, the subjects should fast for at least 10 hours. Water is not prohibited overnight. The next morning, the subjects should administer study drug in fasted state with warm water. The total volume of warm water and suspension is approximately 240 mL. Water is prohibited from 1 hour before dosing to 1 hour after dosing. No food is allowed within 4 hours after dosing. During the study, subjects will receive standardized meals at approximately the same time each day.
Trial: NCT00002343
Drug: Ethambutol hydrochloride
RxNorm normalized name: Ethambutol Hydrochloride
DrugBank: Ethambutol (DB00330)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002343
Drug: Rifabutin
RxNorm normalized name: Rifabutin
DrugBank: Rifabutin (DB00615)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06482775
Drug: dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The dosing and administration will be implemented according to an algorithm based on pain scoring results
Trial: NCT04966234
Drug: Posaconazole 100 MG [Noxafil]
RxNorm normalized name: posaconazole 100 MG [Noxafil]
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Posaconazole is a lipophilic, highly permeable triazole, which is practically insoluble in water. Posaconazole inhibits the enzyme CYP51a (also known as Erg11p or lanosterol demethylase). This enzyme is required for catalysation of an essential step in biosynthesis of ergosterol in filamentous fungi and yeasts.~Posaconazole is favoured over itraconazole and voriconazole with respect to palatability, tolerability and toxicity profile
Trial: NCT04966234
Drug: Posaconazole 40 MG/ML
RxNorm normalized name: posaconazole 40 MG/ML
DrugBank: Posaconazole (DB01263)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Posaconazole is a lipophilic, highly permeable triazole, which is practically insoluble in water. Posaconazole inhibits the enzyme CYP51a (also known as Erg11p or lanosterol demethylase). This enzyme is required for catalysation of an essential step in biosynthesis of ergosterol in filamentous fungi and yeasts.~Posaconazole is favoured over itraconazole and voriconazole with respect to palatability, tolerability and toxicity profile
Trial: NCT05180214
Drug: Bupivacain
RxNorm normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: analgesic
Trial: NCT04729348
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral, daily, dosage per protocol
Trial: NCT04729348
Drug: Lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral, daily, dosage per protocol
Trial: NCT05210504
Drug: L-Lysine
RxNorm normalized name: L-Lysine
DrugBank: Lysine (DB00123)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5g L-lysine in 50ml water, administered orally
Trial: NCT06334874
Drug: Astaxanthin Oral Capsule
RxNorm normalized name: astaxanthin Oral Capsule
DrugBank: Astaxanthin (DB06543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 12 mg of astaxanthin oral capsule
Trial: NCT04854811
Drug: Roflumilast Oral Tablet
RxNorm normalized name: roflumilast Oral Tablet
DrugBank: Roflumilast (DB01656)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Once daily for 12 weeks
Trial: NCT06300177
Drug: D-1553 Tablet
RxNorm normalized name: D
DrugBank: Rosomidnar (DB17154)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: D-1553 is a KRAS inhibitor.
Trial: NCT06300177
Drug: Docetaxel injection
RxNorm normalized name: docetaxel Injection
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Docetaxel, is an anti-tumor drug, significantly reduces the number of free tubules by promoting tubule polymerization into stable microtubules and inhibiting their depolymerization.
Trial: NCT04922983
Drug: Botulinum toxin type A
RxNorm normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: A position similar to the side-plank (Vasisthasana) held for maximal time at least once daily (usual duration: 30 - 90 seconds).